INVO Fertility, Inc. (NASDAQ: IVF)

INVO Bioscience, Inc. (INVO), a company operating in the healthcare services fertility industry, is dedicated to providing innovative solutions in the assisted reproductive technology (ART) marketplace. The company's primary business activities include operating fertility-focused clinics, acquiring profitable in vitro fertilization (IVF) clinics, and selling and distributing its INVOcell technology solution to existing fertility clinics.

INVO's main source of revenue comes from its clinic-based operations and the sale of its INVOcell technology solution. The company's primary products and services include its INVOcell technology solution, IVF procedures, and fertility treatment services. INVO Centers, a segment of the company, offer the INVOcell and IVC procedure, providing a more natural, intimate, and affordable experience for patients compared to traditional IVF treatments. The company's customer base consists of individuals and couples seeking fertility treatment services.

In August 2023, INVO expanded its clinic-based operations through the acquisition of Wisconsin Fertility Institute (WFI), a profitable IVF clinic. This acquisition not only added scale and positive cash flow to the company's operations but also provided a strong presence in the Midwest region of the United States. INVO's competitive advantages lie in its innovative technology solution and expanded clinic-based operations.

The company's key competitors in the ART marketplace include other fertility clinics and companies offering similar fertility treatment services. However, INVO's innovative technology solution and clinic-based operations differentiate it from its competitors. The company's innovative INVOcell technology solution provides a more natural and intimate experience for patients compared to traditional IVF treatments.

In October 2023, INVO entered into a merger agreement with NAYA Biosciences, Inc. (NAYA), a move expected to expand the company's presence in the ART marketplace and provide additional resources to drive growth and innovation. INVO's strategy includes establishing INVO Centers in the United States and abroad, acquiring existing IVF clinics, and selling and distributing its INVOcell technology solution to existing fertility clinics. The company has entered into exclusive distribution agreements for a number of international markets and has established joint ventures and partnerships to establish new INVO Centers.

The global ART marketplace is growing at a strong pace in many parts of the world. According to the European Society for Human Reproduction 2020 ART Fact Sheet, one in six couples worldwide experience infertility problems. Despite this, the worldwide market remains vastly underserved, with only approximately 2.6 million ART cycles performed globally each year, producing around 500,000 babies. This market opportunity is significant, and INVO Bioscience is strategically positioned to capitalize on this growth.